Lv7
4990 积分 2022-06-18 加入
Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses
2天前
已完结
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models
1个月前
已完结
Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection
1个月前
已完结
Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?
1个月前
已完结
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2个月前
已完结
Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study
2个月前
已关闭
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
2个月前
已完结
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
2个月前
已完结
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
2个月前
已完结
皖公网安备34019202002308
